CAESAREA, Israel, July 3, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced preliminary financial results as of and for the three and six months ended June 30, 2025.The Company expects product sales of approximately $525,000 for the three months ended June 30, 2025. While order flow was not impacted by th ...

CAESAREA, Israel, June 25, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that its board of directors approved a rights offering (the "Rights Offering") to all holders of record of the Company's ordinary shares as of 5:00 p.m. Eastern Time on July 9, 2025 (the "Record Date"). Under the Rights Offering, ...

IceCure has 20+ patents in the U.S. and the Company anticipates further market traction upon FDA's marketing authorization decision in early-stage breast cancerCAESAREA, Israel, June 9, 2025 /PRNewswire/ -- IceCure Medical Ltd. (NASDAQ: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced it has received a Notice of Allowance from the United States Patent an ...

IceCure Medical (ICCM) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - Managing MemberEyal Shamir - CEO & DirectorRonen Tsimerman - CFO & COOAnthony Vendetti - Executive Managing DirectorEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants Kemp Dolliver - Director - Research & Senior Analyst Operator Good morning and thank you for standing by. Currently, all the participants are in a listen only mode. After management's discuss ...

IceCure Medical (ICCM) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Company Participants Michael Polyviou - Managing MemberEyal Shamir - CEO & DirectorRonen Tsimerman - CFO & COOAnthony Vendetti - Executive Managing DirectorEduardo Martinez-Montes - Biotechnology Equity Research Associate Conference Call Participants Kemp Dolliver - Director - Research & Senior Analyst Operator Good morning and thank you for standing by. Currently, all the participants are in a listen only mode. After management's discuss ...

IceCure Medical (ICCM) Q1 2025 Earnings Call May 28, 2025 10:00 AM ET Speaker0 Good morning and thank you for standing by. Currently, all the participants are in a listen only mode. After management's discussion, there will be a question and answer session. Please be advised that today's conference is being recorded. I would now like to turn the conference over to Michael Poliview. Please go ahead. Speaker1 Thank you, Ioanni, and welcome to iSecure Medical's conference call to review the financial results a ...

IceCure delivered its proposed post market study plan (the "Plan") to the U.S. Food and Drug Administration ("FDA") as a requisite ahead of the FDA's marketing authorization decision for ProSense® in the treatment of early-stage low risk breast cancer when combined with adjuvant endocrine therapy for women aged 70 and over. The FDA's final marketing authorization decision is expected following review and approval of the plan by the FDA's Center for Devices and Radiological Health ("CDRH"). "During the first ...

CAESAREA, Israel, May 21, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced that it will issue a press release with its financial and operational results as of and for the three months ended March 31, 2025 before the Nasdaq Stock Market opens on Wednesday, May 28, 2025. The Company will also discuss such ...

Final marketing authorization decision for early-stage breast cancer is expected upon the FDA's approval of IceCure's post-market study plan IceCure to engage with potential clinical sites, breast surgeons and radiologists for the post-market study including at the upcoming American Society of Breast Surgeons (ASBrS) Annual Meeting ProSense® would become the first-in-class minimally invasive choice—a major advancement in women's health and a new paradigm in breast cancer care as a simple out-patient proce ...

Two sold-out SBI breast cryoablation courses featured hands-on training with ProSense® IceCure hosted a VIP Exhibitor Hour featuring Dr. Robert C. Ward, a specialist in women's imaging and breast cryoablationCAESAREA, Israel, April 28, 2025 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, today announced its participation a ...